BlackRock, Inc. 13D and 13G filings for Rigel Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-01-25 1:48 pm Purchase | 2023-12-31 | 13G | Rigel Pharmaceuticals, Inc. RIGL | BlackRock Inc. BLK | 1,519,808 8.700% | 51,701 (+3.52%) | Filing |
| 2023-02-03 4:27 pm Sale | 2022-12-31 | 13G | Rigel Pharmaceuticals, Inc. RIGL | BlackRock Inc. BLK | 1,468,106 8.500% | -187,092 (-11.30%) | Filing |
| 2022-02-01 5:08 pm Sale | 2021-12-31 | 13G | Rigel Pharmaceuticals, Inc. RIGL | BlackRock Inc. BLK | 1,655,198 9.700% | -94,144 (-5.38%) | Filing |
| 2021-01-26 6:52 pm Purchase | 2020-12-31 | 13G | Rigel Pharmaceuticals, Inc. RIGL | BlackRock Inc. BLK | 1,749,342 10.400% | 27,432 (+1.59%) | Filing |
| 2020-07-10 10:39 am Purchase | 2020-06-30 | 13G | Rigel Pharmaceuticals, Inc. RIGL | BlackRock Inc. BLK | 1,721,910 10.200% | 251,082 (+17.07%) | Filing |